Market capitalization | JPY1.20t |
Enterprise Value | JPY1.16t |
P/E (TTM) P/E ratio | 20.64 |
EV/FCF (TTM) EV/FCF | 75.04 |
EV/Sales (TTM) EV/Sales | 1.46 |
P/S ratio (TTM) P/S ratio | 1.52 |
P/B ratio (TTM) P/B ratio | 1.38 |
Dividend yield | 3.75% |
Last dividend (FY25) | JPY160.00 |
As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.
14 Analysts have issued a Eisai forecast:
14 Analysts have issued a Eisai forecast:
Dec '24 |
+/-
%
|
||
Revenue | 791,660 791,660 |
6%
6%
|
|
Gross Profit | 627,350 627,350 |
6%
6%
|
|
EBITDA | 92,678 92,678 |
6%
6%
|
EBIT (Operating Income) EBIT | 52,621 52,621 |
11%
11%
|
Net Profit | 58,793 58,793 |
29%
29%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Haruo Naito |
Employees | 11,067 |
Founded | 1936 |
Website | www.eisai.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.